Results for tag: "Harvoni"

Harvoni is a brand of antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It is a combination of two drugs, ledipasvir and sofosbuvir, and is the first all-oral, interferon-free treatment for HCV. Harvoni is a direct-acting antiviral (DAA) drug, meaning it targets the virus itself, rather than the body's immune system. It is used to treat genotypes 1, 4, 5, and 6 of HCV, and is generally taken once daily for 8-12 weeks. Harvoni is a major player in the infectious diseases drugs market, offering a highly effective treatment for HCV. It is the first all-oral, interferon-free treatment for HCV, and is generally well-tolerated with few side effects. Harvoni has been approved for use in many countries, and is widely prescribed for HCV treatment. Companies in the Harvoni market include Gilead Sciences, Inc., Mylan N.V., and Cipla Limited. Show Less Read more